198821-22-6
基本信息
(S)-四氢呋喃-3-基 3-(3-(3-甲氧基-4-(恶唑-5-基)苯基)脲基)苄基氨基甲酸酯
MeriMepodib, VI-21497, VX-497
MERIMEPODIB
VX497
VX-497
VX 497
MMP
VI21497
VI-21497
VI 21497
[(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate
[[3-[[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]carbamic acid (3S)-tetrahydro-3-furanyl ester
Carbamic acid, N-[[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3S)-tetrahydro-3-furanyl ester
物理化学性质
| 沸点 | 571.4±50.0 °C(Predicted) |
| 密度 | 1.36±0.1 g/cm3(Predicted) |
| 储存条件 | Sealed in dry,Room Temperature |
| 溶解度 | ≥45.2 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
| 酸度系数(pKa) | 11.66±0.46(Predicted) |
| 形态 | 固体 |
| 颜色 | Off-white to light yellow |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319 |
| 防范说明 | P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330 |
MERIMEPODIB价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | S6689 | MERIMEPODIB Merimepodib | 198821-22-6 | 5mg | 1170.13元 |
| 2024/04/30 | S6689 | MERIMEPODIB Merimepodib | 198821-22-6 | 25mg | 3350.54元 |
常见问题列表
| Target | Value |
|
IMPDH
() |
VX-497 has antiproliferative effect on lymphoid and keratinocyte cells. The antiproliferative effect of VX-497 in cells is reversed within 48 h of its removal. VX-497 has intermediate antiviral activity against a second group of viruses, which includes HSV-1, parainfluenza-3 virus, BVDV, VEEV, and dengue virus, with IC 50 s ranging from 6 to 19 μM. VX-497 is 100-fold more potent, with an IC 50 of 380 nM and a corresponding CC 50 of 5.2 μM, for a therapeutic index of 14. The antiviral activity of VX-497 in HepG2.2.2.15 cells is reversed threefold by the addition of guanosine.
Oral administration of VX-497 inhibits the primary IgM antibody response in a dose-dependent manner, with an ED 50 value of appr 30-35 mg/kg in mice. Single daily dosing of VX-497 is observed to be as effective as twice-daily dosing in this model of immune activation. GVHD developed in the vehicle-treated allografted F1 mice and treatment with VX-497 improved all manifestations of the disease significantly. The 2.9-fold increase in spleen weight in allografted animals is reduced to a 1.6-fold increase in the VX-497-treated mice. Serum IFN-gamma levels are increased 54-fold in the vehicle group while there is a 7.4-fold increase in VX-497-treated animals.